.png){kind=icon}
Return
Darolutamide: First Approval
.png){kind=icon}
PRE
AI
DOI：10.1007/s40265-019-01212-y.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Darolutamide (NUBEQA (TM)) is a structurally distinct non-steroidal androgen receptor antagonist being developed by Orion and Bayer as a treatment for prostate cancer. Based on positive results in the phase III ARAMIS trial, darolutamide was recently approved in the USA for the treatment of men with non-metastatic castration-resistant prostate cancer. This article summarizes the milestones in the development of darolutamide leading to this first approval.
Keywords:
ODM-201
SAFETY
ARADES
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
14.4
Papers:
8.4K
Citations:
2.3W
Organization
No organization information available
Cited Papers
Large‐scale volcanism associated with coronae on Venus: Implications for formation and evolution
PREAI
ShareSavePharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.png)
EUROPEAN UROLOGY
OAAI
EUROPEAN UROLOGYIF25.2
OAAIShareSaveDarolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer modelsOAAI
OAAIShareSaveStructure and composition of the neutral upper atmosphere of Mars from the MAVEN NGIMS investigationOAAI
OAAIShareSaveDiscovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapiesSCIENTIFIC REPORTSOAAI
SCIENTIFIC REPORTSIF3.9
OAAIShareSave
View more